Abstract
No public abstract is available from the verified source records.
Quanji Wang, Linhan Li, Mengzhu Li, Xingbo Li, Yaorui Wang, Yanchao Liu, Kai Shu, Zhuowei Lei
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The epidemiology of pituitary adenomas
10.1016/j.ecl.2020.04.002 · 2020
Diagnosis and treatment of pituitary adenomas: a review
10.1001/jama.2016.19699 · 2017
Diagnosis and management of pituitary adenomas: a review
10.1001/jama.2023.5444 · 2023
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal
10.1530/erc-23-0021 · 2023
Invasive, atypical and aggressive pituitary adenomas and carcinomas
10.1016/j.ecl.2014.10.008 · 2015
The clinical features, recurrence risks and surgical strategies of bone invasive pituitary adenomas
10.1016/j.clineuro.2020.106455 · 2021
Expression and clinical significance of Cathepsin K and MMPs in invasive non-functioning pituitary adenomas
2022
PKCtheta regulates pituitary adenoma bone invasion by activating osteoclast in NF-kappaB/IL-1beta-dependent manner
10.3390/cancers15051624 · 2023
Functions and mechanisms of tumor necrosis factor-alpha and noncoding RNAs in bone-invasive pituitary adenomas
10.1158/1078-0432.ccr-18-0472 · 2018
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
The miR-19a/Cylindromatosis Axis regulates pituitary adenoma bone invasion by promoting osteoclast differentiation
10.3390/cancers16020302 · 2024
TNF-alpha can promote membrane invasion by activating the MAPK/MMP9 signaling pathway through autocrine in bone-invasive pituitary adenoma
10.1111/cns.14749 · 2024
LncRNA MEG8 promotes TNF-alpha expression by sponging miR-454-3p in bone-invasive pituitary adenomas
10.18632/aging.203048 · 2021
A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma
10.1093/neuonc/noad148 · 2024
Celastrol induces apoptosis and autophagy via the AKT/mTOR signaling pathway in the pituitary ACTH-secreting adenoma cells
10.1007/s11596-022-2568-6 · 2022
Triptolide suppresses growth and hormone secretion in murine pituitary corticotroph tumor cells via NF-kappaB signaling pathway
10.1016/j.biopha.2017.08.127 · 2017
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway
10.1016/j.lfs.2017.12.037 · 2018
Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis
10.1038/s41467-021-22454-z · 2021
Celastrol attenuates bone erosion in collagen-induced arthritis mice and inhibits osteoclast differentiation and function in RANKL-induced RAW264.7
10.1016/j.intimp.2014.12.012 · 2015
Celastrol ameliorates osteoarthritis via regulating TLR2/NF-kappaB signaling pathway
2022
Mutations Y493G and K546D in human HSP90 disrupt binding of celastrol and reduce interaction with Cdc37
10.1002/2211-5463.12081 · 2016
Advancements in molecular diagnosis and pharmacotherapeutic strategies for invasive pituitary adenomas
10.1002/iid3.70098 · 2024
Celastrol as an emerging anticancer agent: current status, challenges and therapeutic strategies
10.1016/j.biopha.2023.114882 · 2023
Celastrol, an active constituent of the TCM plant Tripterygium wilfordii Hook.F., inhibits prostate cancer bone metastasis
10.1038/pcan.2016.61 · 2017
A comprehensive review on celastrol, triptolide and triptonide: insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes
10.1016/j.biopha.2023.114705 · 2023
Celastrol attenuates RANKL-induced Osteoclastogenesis in vitro and reduces titanium particle-induced Osteolysis and Ovariectomy-induced bone loss in vivo
2021
Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence
2025
Role of Cathepsin K in bone invasion of pituitary adenomas: a dual mechanism involving cell proliferation and osteoclastogenesis
10.1016/j.canlet.2025.217443 · 2025
Early immunomodulation by magnesium ion: catalyst for superior osteogenesis
2023
Cellular heterogeneity and inflammatory profiles in gliomas: single-cell transcriptomic insights
2025
Toward precision oncology: leveraging bone metastatic organoid models for mechanistic, translational, and therapeutic discovery
2026
Celastrol inhibits LL37-induced rosacea by inhibiting ca(2+)/CaMKII-mTOR-NF-kappaB activation
10.1016/j.biopha.2022.113292 · 2022
Celastrol, an NF-kappaB inhibitor, ameliorates hypercalciuria and articular cartilage lesions in a mouse model of secondary osteoporosis
10.1016/j.jphs.2016.02.001 · 2016
Celastrol attenuates renal injury in diabetic rats via MAPK/NF-kappaB pathway
10.1002/ptr.6314 · 2019
Targeting HSP90 as a novel therapy for Cancer: mechanistic insights and translational relevance
10.3390/cells11182778 · 2022
Targeting HSP90 for Cancer therapy: current Progress and emerging prospects
10.1021/acs.jmedchem.4c00966 · 2024
Discovery of novel Celastrol derivatives as Hsp90-Cdc37 interaction disruptors with antitumor activity
10.1021/acs.jmedchem.9b01290 · 2019
HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
10.1186/1476-4598-9-79 · 2010
No additional external references are available.